Effects of roxadustat on thyroid function in patients with renal anemia undergoing peritoneal dialysis
10.3760/cma.j.cn341190-20240131-00139
- VernacularTitle:罗沙司他对腹膜透析肾性贫血患者甲状腺功能的影响
- Author:
Daoyan WANG
1
;
Zuoyan SUN
1
;
Zhongguang CHEN
1
Author Information
1. 临沂市中心医院药学部，临沂 276000
- Publication Type:Journal Article
- Keywords:
Kidney failure, chronic;
Anemia;
Prolyl-hydroxylase inhibitors;
Thyroid function tests;
Hypoxia-inducible factor 1;
Erythropoietin;
Peritoneal dialysis;
Risk
- From:
Chinese Journal of Primary Medicine and Pharmacy
2025;32(1):83-87
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effects of roxadustat on thyroid function in patients with renal anemia undergoing peritoneal dialysis.Methods:After applying the inclusion and exclusion criteria, a retrospective analysis was conducted on the clinical data of 151 patients undergoing peritoneal dialysis who were treated with either roxadustat or erythropoietin at Linyi Central Hospital from January 2019 to December 2023. The patients were divided into two groups based on their treatment: roxadustat group ( n = 88) and erythropoietin group ( n = 63). Patient age, sex, body mass index, urine output, duration of illness, primary disease, comorbidities, estimated glomerular filtration rate, total parathyroid hormone levels, and thyroid nodule status were recorded. Thyroid-stimulating hormone (TSH), free triiodothyronine, and free thyroxine levels before and after treatment were compared between the two groups. A decrease in TSH of more than one-third after treatment compared with the pre-treatment level was defined as a significant decrease in TSH. Multivariate logistic regression analysis was conducted to investigate the independent risk factors associated with a significant decrease in TSH in patients with renal anemia undergoing peritoneal dialysis. Results:After treatment, the roxadustat group showed significant decreases in TSH [1.84 (1.06, 2.67) U/L] and FT4 [(11.82 ± 3.56) pmol/L] compared with pre-treatment levels [2.58 (1.67, 3.42) U/L, (14.89 ± 3.27) pmol/L, Z = -3.42, t = -5.97, both P < 0.05]. After treatment, both TSH and FT4 levels were significantly lower in the roxadustat group than those in the erythropoietin group [2.80 (1.61, 3.78) U/L, (15.49 ± 3.24) pmol/L, Z = -3.36, t = 6.49, both P < 0.05]. Multivariate logistic regression analysis indicated that the use of roxadustat was an independent risk factor for a significant decrease in TSH in patients with renal anemia undergoing peritoneal dialysis [ OR = 7.621, 95% CI (3.195, 18.178)]. Conclusions:Roxadustat may lower TSH and FT4 levels in patients with renal anemia undergoing peritoneal dialysis.
